For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

Vertex has entered a reimbursement agreement with NHS England enabling eligible SCD patients to access Casgevy in the public health system.

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

A new gene editing treatment has been approved for use in the NHS, which will help treat sickle cell disease patients ...

One sickle cell patient told ITV News the new gene therapy being rolled out for use on the NHS means they "finally have something to look towards". | ITV National News ...

In addition to the prolonged pain and suffering endured by sickle cell patients, a Washington University School of Medicine study has concluded that there could be a significant impact on cognitive ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...

For those living with sickle cell disease, daily life is a series of ... can be as significant as the physical symptoms. Many patients face limitations on career choices, social interactions ...

Right now, approximately 20 billion red blood cells are busy traveling through your blood vessels. They are delivering oxygen ...

Gallbladder issues are a frequent but manageable complication of sickle cell disease. Awareness of the symptoms and risk factors, combined with regular medical care, can help patients address ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy ...

SSM Health Cardinal Glennon Children's Hospital partners with Eye See Me African Bookstore to provide books promoting ...